CalciMedica Announces Presentations at Upcoming Medical Meetings
CalciMedica (Nasdaq: CALC), a clinical-stage biopharmaceutical company, has announced its participation in two major medical conferences in May 2025. At Digestive Disease Week (DDW) 2025 in San Diego, CSO Kenneth A. Stauderman will present research on acute pancreatitis patients with SIRS and their volume distribution compared to healthy volunteers.
Additionally, Chief Medical Officer Sudarshan Hebbar will participate in the American Society of Nephrology (ASN) 3rd Acute Kidney Injury Conference in Leesburg, VA. Dr. Hebbar will deliver an oral presentation on AKI Clinical Trial Design and participate in a panel discussion on non-academic careers in science. The company, which focuses on developing CRAC channel inhibition therapies for inflammatory and immunologic illnesses, will make the presentations available on their IR website.
CalciMedica (Nasdaq: CALC), un'azienda biofarmaceutica in fase clinica, ha annunciato la sua partecipazione a due importanti conferenze mediche nel maggio 2025. Alla Digestive Disease Week (DDW) 2025 di San Diego, il CSO Kenneth A. Stauderman presenterà una ricerca sui pazienti con pancreatite acuta e SIRS, analizzando la distribuzione del volume rispetto a volontari sani.
Inoltre, il Chief Medical Officer Sudarshan Hebbar parteciperà alla 3ª Conferenza sull'Insufficienza Renale Acuta (AKI) della American Society of Nephrology (ASN) a Leesburg, VA. Il dott. Hebbar terrà una presentazione orale sul design dei trial clinici per AKI e prenderà parte a una tavola rotonda sulle carriere scientifiche fuori dal contesto accademico. L'azienda, specializzata nello sviluppo di terapie di inibizione dei canali CRAC per malattie infiammatorie e immunologiche, renderà disponibili le presentazioni sul proprio sito IR.
CalciMedica (Nasdaq: CALC), una compañía biofarmacéutica en etapa clínica, ha anunciado su participación en dos importantes conferencias médicas en mayo de 2025. En la Digestive Disease Week (DDW) 2025 en San Diego, el CSO Kenneth A. Stauderman presentará una investigación sobre pacientes con pancreatitis aguda y SIRS, comparando la distribución de volumen con voluntarios sanos.
Además, el Director Médico Sudarshan Hebbar participará en la 3ª Conferencia sobre Lesión Renal Aguda (AKI) de la American Society of Nephrology (ASN) en Leesburg, VA. El Dr. Hebbar ofrecerá una presentación oral sobre el diseño de ensayos clínicos para AKI y formará parte de un panel sobre carreras científicas fuera del ámbito académico. La compañía, que se centra en desarrollar terapias de inhibición de canales CRAC para enfermedades inflamatorias e inmunológicas, pondrá las presentaciones a disposición en su sitio web de Relaciones con Inversionistas.
CalciMedica (나스닥: CALC)는 임상 단계 바이오제약 회사로서 2025년 5월 두 개의 주요 의학 학회에 참가한다고 발표했습니다. 샌디에이고에서 열리는 Digestive Disease Week (DDW) 2025에서 CSO Kenneth A. Stauderman는 급성 췌장염 환자 중 SIRS가 있는 환자들의 체액 분포를 건강한 자원자와 비교한 연구를 발표할 예정입니다.
또한, 최고 의료 책임자 Sudarshan Hebbar 박사는 버지니아주 리즈버그에서 열리는 미국 신장학회(ASN) 제3회 급성 신손상(AKI) 학회에 참여합니다. Hebbar 박사는 AKI 임상시험 설계에 관한 구두 발표를 진행하고, 과학 분야 비학술 경력에 관한 패널 토론에도 참여할 예정입니다. 염증 및 면역 질환 치료를 위한 CRAC 채널 억제제 개발에 주력하는 이 회사는 발표 자료를 IR 웹사이트에 공개할 계획입니다.
CalciMedica (Nasdaq : CALC), une société biopharmaceutique en phase clinique, a annoncé sa participation à deux grandes conférences médicales en mai 2025. Lors de la Digestive Disease Week (DDW) 2025 à San Diego, le CSO Kenneth A. Stauderman présentera des recherches sur des patients atteints de pancréatite aiguë avec SIRS et la répartition de leur volume comparée à celle de volontaires sains.
De plus, le Chief Medical Officer Sudarshan Hebbar participera à la 3e conférence sur la lésion rénale aiguë (AKI) de l'American Society of Nephrology (ASN) à Leesburg, en Virginie. Le Dr Hebbar donnera une présentation orale sur la conception des essais cliniques en AKI et prendra part à une table ronde sur les carrières scientifiques hors milieu académique. L'entreprise, spécialisée dans le développement de thérapies d'inhibition des canaux CRAC pour les maladies inflammatoires et immunologiques, mettra les présentations à disposition sur son site web IR.
CalciMedica (Nasdaq: CALC), ein biopharmazeutisches Unternehmen in der klinischen Entwicklungsphase, hat seine Teilnahme an zwei wichtigen medizinischen Konferenzen im Mai 2025 angekündigt. Auf der Digestive Disease Week (DDW) 2025 in San Diego wird CSO Kenneth A. Stauderman Forschungsergebnisse zu Patienten mit akuter Pankreatitis und SIRS sowie deren Volumenverteilung im Vergleich zu gesunden Freiwilligen vorstellen.
Zusätzlich wird der Chief Medical Officer Sudarshan Hebbar an der 3. Akuten Nierenschädigungskonferenz (AKI) der American Society of Nephrology (ASN) in Leesburg, VA, teilnehmen. Dr. Hebbar wird einen Vortrag zum Design klinischer Studien bei AKI halten und an einer Podiumsdiskussion über nicht-akademische Karrieren in der Wissenschaft teilnehmen. Das Unternehmen, das sich auf die Entwicklung von CRAC-Kanal-Inhibitoren für entzündliche und immunologische Erkrankungen spezialisiert hat, wird die Präsentationen auf seiner IR-Webseite zur Verfügung stellen.
- None.
- None.
Details for the presentations are as follows:
Poster Presentation at DDW 2025
Presentation Title: Patients with Acute Pancreatitis (AP) and Accompanying Systemic Inflammatory Response Syndrome (SIRS) Have a Larger Volume of Distribution Compared to Healthy Volunteers
Presenter: Kenneth A. Stauderman, Ph.D., co-Founder and Chief Scientific Officer of CalciMedica
Session Title: Clinical Acute Pancreatitis: Management
Session Date and Time: Saturday, May 3, 12:30-1:30 p.m. PT
Oral Presentation at ASN 3rd Acute Kidney Injury: From Bench to Bedside Conference
Presentation Title: Experiences with AKI Clinical Trial Design
Presenter: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica
Session Title: Session 5: Clinical Trials and Drug Discovery – Part 2
Session Date and Time: Tuesday, May 6, 8:00-10:00 a.m. ET
Panel Discussion at ASN 3rd Acute Kidney Injury: From Bench to Bedside Conference
Panel Title: Session 3: Roundtable Discussions - Non-Academic Careers in Science
CalciMedica Participant: Sudarshan Hebbar, M.D., Chief Medical Officer of CalciMedica
Panel Date and Time: Wednesday, May 7, 4:00-4:30 p.m. ET
The posters will be available following the sessions on the Medical Events & Presentations section of CalciMedica's IR website at https://ir.calcimedica.com/news-events/medical-events-publications.
About CalciMedica
CalciMedica is a clinical-stage biopharmaceutical company focused on developing novel CRAC channel inhibition therapies for inflammatory and immunologic diseases. CalciMedica's proprietary technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory and immunologic diseases for which there are currently no approved therapies. CalciMedica's lead product candidate Auxora™ has demonstrated positive and consistent clinical results in multiple completed efficacy clinical trials. CalciMedica has announced data for a Phase 2b trial (called CARPO – NCT04681066) in patients with acute pancreatitis (AP) and accompanying systemic inflammatory response syndrome (SIRS). The Company has also completed a Phase 2 trial (called CARDEA – NCT04345614) in patients with COVID pneumonia. The Company is currently conducting a Phase 2 trial (called KOURAGE – NCT06374797) in patients with acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF) and continuing to support the ongoing Phase 1/2 trial (called CRSPA – NCT04195347) in pediatric patients with asparaginase-induced pancreatic toxicity (AIPT). CalciMedica was founded by scientists from Torrey Pines Therapeutics and the Harvard CBR Institute for Biomedical Research, and is headquartered in La Jolla, CA. For more information, please visit www.calcimedica.com.
Contact Information
Argot Partners
calcimedica@argotpartners.com
(212) 600-1902
View original content to download multimedia:https://www.prnewswire.com/news-releases/calcimedica-announces-presentations-at-upcoming-medical-meetings-302430944.html
SOURCE CalciMedica, Inc.
FAQ
What medical conferences will CalciMedica (CALC) present at in May 2025?
What research will CalciMedica (CALC) present at DDW 2025?
What topics will Dr. Hebbar discuss at the ASN Acute Kidney Injury Conference?
Where can investors find CalciMedica's (CALC) medical presentation materials?
What therapeutic focus does CalciMedica (CALC) have?
